Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease

Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023

Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress

Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD

Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Data Review by the Independent DSMB reported for Phase 2b/3 Trial of ANAVEX®2-73 for AD

Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits

Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)